Nathalie Villeneuve

Nathalie Villeneuve

Auto-generated profile, based on publicly available information

Nathalie Villeneuve

Pediatric Neurology Department, La Timone Children Hospital, APHM, Marseille, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Neurology
Verified
Journal Article
Closed access
ZGZeynep Gokce-Samar
Zeynep Gokce-Samar
AVAnnalisa Vetro
Annalisa Vetro
JBJulitta De Bellescize
Julitta De Bellescize
TPTiziana Pisano
Tiziana Pisano
LMLaloe Monteiro
Laloe Monteiro
GLGaetan Lesca
Gaetan Lesca
Heterozygous variants in RAR-related orphan receptor B (RORB) have recently been associated with susceptibility to idiopathic generalized epilepsy. However, few reports have been published so far describing pathogenic variants of this gene in patients with epilepsy and intellectual disability (ID). In this study, we aimed to delineate the epilepsy phenotype associated with RORB pathogenic variants and to provide arguments in favor of the pathogenicity of variants. Through an international collaboration, we analyzed seizure characteristics, EEG data, and genotypes of a cohort of patients with heterozygous variants in RORB. To gain insight into disease mechanisms, we performed ex vivo cortical electroporation in mouse embryos of 5 selected variants, 2 truncating and 3 missense, and evaluated on expression and quantified changes in axonal morphology. We identified 35 patients (17 male, median age 10 years, range 2.5-23 years) carrying 32 different heterozygous variants in RORB, including 28 single-nucleotide variants or small insertions/deletions (12 missense, 12 frameshift or nonsense, 2 splice-site variants, and 2 in-frame deletions), and 4 microdeletions; de novo in 18 patients and inherited in 10. Seizures were reported in 31/35 (89%) patients, with a median age at onset of 3 years (range 4 months-12 years). Absence seizures occurred in 25 patients with epilepsy (81%). Nineteen patients experienced a single seizure type: absences, myoclonic absences, or absences with eyelid myoclonia and focal seizures. Nine patients had absence seizures combined with other generalized seizure types. One patient had presented with absences associated with photosensitive occipital seizures. Three other patients had generalized tonic-clonic seizures without absences. ID of variable degree was observed in 85% of the patients. Expression studies in cultured neurons showed shorter axons for the 5 tested variants, both truncating and missense variants, supporting an impaired protein function. In most patients, the phenotype of the RORB-related disorder associates absence seizures with mild-to-moderate ID. In silico and in vitro evaluation of the variants in our cohort, including axonal morphogenetic experiments in cultured neurons, supports their pathogenicity, showing a hypomorphic effect.

23 June 2026 in Neurology
Verified
Journal Article
Closed access
PDF file
FRFlorence Riccardi
Florence Riccardi
BDBeatrice Desnous
Beatrice Desnous
EBEmilie Borloz
Emilie Borloz
ALAnne Lepine
Anne Lepine
CLCaroline Lacoste
Caroline Lacoste
MMMathieu Milh
Mathieu Milh
Background and ObjectivesDevelopmental and epileptic encephalopathies (DEEs) with early burst-suppression EEG (EIDEE-BS) are among the most severe neonatal epileptic syndromes, typically presenting...

9 October 2018 in Epilepsia
Verified
Journal Article
Open access
PDF file
AMAileen McGonigal
Aileen McGonigal
Jean-Arthur Micoulaud-FranchiJean-Arthur Micoulaud-Franchi
Jean-Arthur Micoulaud-Franchi
NVNathalie Villeneuve
Nathalie Villeneuve
ALAnne Lepine
Anne Lepine
MVMarine Viellard
Marine Viellard
MMMathieu Milh
Mathieu Milh

25 April 2026 in Epilepsia
Verified
Journal Article
Open access
MHMira Hamze
Mira Hamze
RWRobyn Whitney
Robyn Whitney
DVDorothée Ville
Dorothée Ville
NVNathalie Villeneuve
Nathalie Villeneuve
AHAnna‐Maria Hartmann
Anna‐Maria Hartmann
IIIgor Imedyna60
Igor Imedyna60
Objective: This study was undertaken to characterize the functional impact of novel SLC12A5 variants in two unrelated patients with early onset developmental and epileptic encephalopathy (DEE) and to investigate the mechanisms underlying KCC2 dysfunction. Methods: Clinical, genetic, and functional analyses were performed in two patients (Cases A and B) with DEE. SLC12A5 encodes two KCC2 splice isoforms (KCC2a and KCC2b). Functional effects of the identified variants on KCC2b ion transport, phosphorylation, mRNA processing, and KCC2‐dependent synaptogenesis were assessed using in vitro assays in heterologous expression systems and primary neurons, supported by in silico structural modeling. Results: Both patients developed severe neonatal onset DEE characterized by developmental delay, axial hypotonia, extrapyramidal features, and bilateral migratory seizures within 24 h of birth. Both cases resulted in early mortality (Case A at 9 years; Case B at 6 months). Sequencing revealed distinct biallelic compound heterozygous SLC12A5 variants in both individuals, each inherited from one unaffected parent. Functional analyses demonstrated that in Case A, one variant markedly reduced KCC2‐mediated ion transport, whereas the second variant preserved transport activity but exhibited an altered phosphorylation profile at Ser940, located on the intracellular C ‐terminal region. This variant also disrupted wild‐type (WT) KCC2‐dependent excitatory synapse formation in immature rat hippocampal neurons. In Case B, one variant disrupted normal mRNA transcript processing consistent with loss of expression, and the second variant exhibited reduced ion transport activity. Significance: These data demonstrate that SLC12A5 ‐related DEE can result from combined impairment of KCC2‐dependent chloride homeostasis and disruption of chloride‐independent KCC2 functions critical for early neuronal development. This work expands the mutational and mechanistic spectrum of SLC12A5 ‐DEE and highlights the importance of KCC2 regulatory roles in early brain development, providing new knowledge and tools for basic research and potential avenues for targeted precision therapies.